pEPito-driven PEDF Expression Ameliorates Diabetic Retinopathy Hallmarks

Area of Science:

• Ophthalmology
• Genetics
• Diabetology

Background:

• Diabetic retinopathy (DR) is a major diabetes complication, causing retinal microvascular changes and neovascularization due to chronic hyperglycemia.
• Current DR treatments like laser photocoagulation and antiangiogenic agents have significant side effects and limitations.
• An imbalance favoring proangiogenic factors (VEGF) over antiangiogenic factors (PEDF) drives pathological angiogenesis in DR.

Purpose of the Study:

• To evaluate the therapeutic potential of gene therapy with the episomal vector pEPito for overexpressing pigment epithelial-derived factor (PEDF) in diabetic retinopathy.
• To assess the long-term efficacy and safety of pEPito-mediated PEDF delivery in preclinical models of DR.

Main Methods:

• Utilized the engineered episomal vector pEPito for sustained gene expression in retinal cells.
• Administered a single subretinal injection of pEPito-PEDF into diabetic mice and human retinal pigment epithelial cells in vitro.
• Measured PEDF and VEGF levels, glucose transporter GLUT1 expression, and microglial reactivity post-injection.

Main Results:

• pEPito successfully overexpressed PEDF for up to three months in vitro and in vivo.
• Subretinal injection of pEPito-PEDF led to increased PEDF and decreased VEGF levels in diabetic mouse retinas.
• Gene therapy significantly reduced glucose transport (GLUT1) and inflammation (microglial reactivity), key hallmarks of DR.

Conclusions:

• Gene therapy with pEPito-PEDF demonstrates significant therapeutic potential for diabetic retinopathy.
• Sustained PEDF overexpression via pEPito offers a promising long-term treatment strategy for DR by targeting key pathological pathways.
• This approach may overcome limitations of current DR treatments, offering a novel therapeutic avenue.